Table 1. Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.

Age groups	18–60 years						> 60 years							18–60 years
Primary vaccine dose	7.5 μg(n = 39)			30 μg + Adjuvant (n = 38)	30 μg +Adjuvant (n = 60)		7.5 μg(n = 36)		30 μg +Adjuvant(n = 41)			30 μg +Adjuvant(n = 58)		No previous H5N1 vaccine(n = 50)
Booster dose	7.5 μg Booster group				Clade 2 Booster Group		7.5 μg Booster group					Clade 2 Booster Group		Clade 2 Priming group
	%	95% CI	%	95% CI	%	95% CI	%	95% CI		%	95% CI	%	95% CI	%	95% CI
Injection site reactions
Pain	20.5	9.3;36.5	28.9	15.4;45.9	61	47.4;73.5	8.3	1.8;22.5		7.3	1.5;19.9	28.1	17.0;41.5	44	30;58.7
Erythema	12.8	4.3;27.4	13.2	4.4;28.1	25.4	15.0;38.4	2.8	0.1;14.5		0.0	0.0;8.6	12.3	5.1;23.7	10	3.3;21.8
Swelling	0	0;9.0	2.6	0.1;13.8	15.3	7.2;27	5.6	0.7;18.7		0.0	0.0;8.6	8.8	2.9;10.3	8	2.2;19.2
Induration*	7.7	1.6;20.9	2.6	0.1;13.8	25.4	15;38.4	0.0	0.0;9.7		0.0	0.0;8.6	8.8	2.9;10.3	14	5.8;26.7
Ecchymosis*	0.0	0.0;9.0	0	0.0;9.3	5.1	1.1;14.1	0.0	0.0;9.7		2.4	0.1;9.7	5.2	1.9;10.9	2	1.3;16.5
Systemic Reactions
Fever*	0.0	0.1;12.9	2.6	01;13.8	3.4	0.4;11.7	2.8	0.1;14.5		2.4	0.1;12.9	5.3	1.1;14.6	4	0.5;13.7
Headache	17.9	7.5;33.5	18.4	7.7;34.3	30.5	19.2;43.9	13.9	4.7;29.5		9.8	2.7;23.1	19.3	10;31.9	26	14.6;40.3
Malaise*	5.1	0.6;17.3	7.9	1.7;21.4	16.9	8.4;29	2.8	0.1;14.5		2.4	0.1;12.9	10.5	4.0;21.5	16	2.2;19.2
Myalgia	5.1	0.6;17.3	7.9	1.7;21.4	18.6	9.7;30.9	5.6	0.7;18.7		4.9	0.6;16.5	10.5	4.0;21.5	10	1.3;21.8
Shivering*	0.0	0.0;9.0	5.3	0.6;17.7	6.8	1.9;16.5	0.0	0.0;9.7		0.0	0.0;8.6	5.3	1.1;14.6	6	0.0;7.1

n = number of participants’ data analysed, based on the number of subjects who received at least 1 dose of vaccine

*participants were asked to specifically record these adverse events for 3-days after vaccination